Multicenter comparison of Etest, Vitek2 and BD Phoenix to broth microdilution for beta-lactam susceptibility testing of Streptococcus pneumonia
- PMID: 38801483
- PMCID: PMC11271421
- DOI: 10.1007/s10096-024-04847-2
Multicenter comparison of Etest, Vitek2 and BD Phoenix to broth microdilution for beta-lactam susceptibility testing of Streptococcus pneumonia
Abstract
Purpose: To assess performance of Etest®, Vitek®2 and BD Phoenix™ to determine the susceptibility of Streptococcus pneumoniae strains to penicillin, ampicillin and cefotaxime.
Methods: Sixty unique S. pneumoniae challenge strains were selected to cover a wide range of penicillin, ampicillin and cefotaxime minimal inhibitory concentrations (MICs). Strains were analyzed in four different Belgian laboratories. Etest® benzylpenicillin (BEN), ampicillin/amoxicillin (AMP) and cefotaxime (CTA) (bioMérieux), Vitek®2 AST-ST03 (bioMérieux) and BD Phoenix™ SMIC/ID-11 testing were each performed in two different labs. Results were compared to Sensititre® broth microdilution (BMD) (Thermo Fisher Scientific) results. MIC results were interpreted using EUCAST non-meningitis breakpoints (v 13.0).
Results: Essential agreement (EA) was ≥ 90% for all methods compared to BMD, except for Etest® BEN on Oxoid plate (58.3%), Etest® AMP (both on Oxoid (65.8%) and BD BBL plate (84.2%)). Categorical agreement (CA) for penicillin was only ≥ 90% for Vitek®2, for other methods CA ranged between 74 and 84%. CA for AMP was for all methods < 90% (range 75.8-88.3%) and CA for CTA was between 87 and 90% for all methods except for Etest on Oxoid plate (79.2%).
Conclusions: Our study indicates that Vitek®2 and BD Phoenix™ are reliable for providing accurate pneumococcal susceptibility results for BEN, AMP and CTA. Using Etest BEN or AMP on Oxoid plate carries a risk of underestimating the MIC and should be interpreted with caution, especially when the obtained MIC is 1 or 2 doubling dilutions below the S or R clinical breakpoint.
Keywords: Antimicrobial susceptibility testing; Beta-lactam; EUCAST breakpoints; Streptococcus pneumoniae.
© 2024. The Author(s).
Conflict of interest statement
The authors have no relevant financial or non-financial interests to disclose.
Figures

Similar articles
-
Comparison of BD phoenix to vitek 2, microscan MICroSTREP, and Etest for antimicrobial susceptibility testing of Streptococcus pneumoniae.J Clin Microbiol. 2009 Nov;47(11):3557-61. doi: 10.1128/JCM.01137-09. Epub 2009 Sep 9. J Clin Microbiol. 2009. PMID: 19741088 Free PMC article.
-
Variability of β-lactam susceptibility testing for Streptococcus pneumoniae using 4 commercial test methods and broth microdilution.Diagn Microbiol Infect Dis. 2016 Mar;84(3):240-5. doi: 10.1016/j.diagmicrobio.2015.11.014. Epub 2015 Nov 17. Diagn Microbiol Infect Dis. 2016. PMID: 26707068
-
[Evaluation of the BD phoenix automated microbiology system SMIC/ID-2 panel for antimicrobial susceptibility testing of Streptococcus pneumoniae].Korean J Lab Med. 2009 Jun;29(3):212-7. doi: 10.3343/kjlm.2009.29.3.212. Korean J Lab Med. 2009. PMID: 19571618 Korean.
-
Predicting Oral Beta-lactam susceptibilities against Streptococcus pneumoniae.BMC Infect Dis. 2021 Jul 13;21(1):679. doi: 10.1186/s12879-021-06341-y. BMC Infect Dis. 2021. PMID: 34256734 Free PMC article.
-
Multicenter interlaboratory study of routine systems for the susceptibility testing of temocillin using a challenge panel of multidrug-resistant strains.Eur J Clin Microbiol Infect Dis. 2023 Dec;42(12):1477-1483. doi: 10.1007/s10096-023-04681-y. Epub 2023 Oct 23. Eur J Clin Microbiol Infect Dis. 2023. PMID: 37870713
Cited by
-
Prediction of antimicrobial susceptibility of pneumococci based on whole-genome sequencing data: a direct comparison of two genomic tools to conventional antimicrobial susceptibility testing.J Clin Microbiol. 2025 Feb 19;63(2):e0107924. doi: 10.1128/jcm.01079-24. Epub 2024 Dec 31. J Clin Microbiol. 2025. PMID: 39745445 Free PMC article.
References
-
- European Centre for Disease Prevention and Control (2022) Antimicrobial resistance in the EU/EEA (EARS-Net) - Annual Epidemiological Report 2021. ECDC, Stockholm
-
- EUCAST (2019) Warning against the use of gradient tests for benzylpenicillin MIC in Streptococcus pneumoniae. https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Warnings/Wa.... Accessed 14 September 2023
-
- CLSI (2015) Verification of Commercial Microbial Identification and Antimicrobial Susceptibility Testing Systems. 1st ed. CLSI guideline M52. Wayne, PA: Clinical and Laboratory Standards Institute
-
- International Standard Organisation ISO 20776-2:2021 (2021) Clinical laboratory testing and in vitro diagnostic test systems_Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices. Part 2_Evaluation of performance of antimicrobial susceptibility test devices against reference broth micro-dilution AFNOR. Genève
-
- The European Committee on Antimicrobial Susceptibility Testing (2023) Breakpoint tables for interpretation of MICs and zone diameters. Version 13.0
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases